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ABSTRACT
NOTCH2 is a transmembrane receptor that is part of the Notch receptor family, known for
controlling cell differentiation and function. Notch receptors play a crucial role in skeletal
development and bone homeostasis. Hajdu Cheney Syndrome (HCS) is a rare monogenic disorder
affecting the skeleton caused by a gain-of-function mutation in NOTCH2. Antisense
oligonucleotides (ASO) are sequence-specific single-stranded nucleic acids that bind to target
mRNA and initiate mRNA degradation. While previous work has explored the role of Notch2
ASOs in osteoblasts and osteoclasts, this paper explores the role of Notch2 and Notch2 ASOs in
cells of cartilage tissue. The effect of Notch2 ASOs on Notch2 were tested in chondrocytes of a
murine model of HCS (Notch2tm1.1Ecan) in vitro and in vivo. Notch2 ASO downregulated Notch2
in chondrocytes of both Notch2wt/wt mice and Notch2tm1.1Ecan mice. Notch target genes Hes1, Hey1,
Hey2, and HeyL were amplified in Notch2tm1.1Ecan mice, indicating the presence of the HCS gainof-function Notch2 mutation. Notch2 ASOs significantly downregulated Notch2 and Notch target
genes in chondrocytes from Notch2tm1.1Ecan mice. The mutant gene Notch26955C>T was only detected
in Notch2tm1.1Ecan mice and was downregulated by a mutant specific Notch26955C>T ASO. In
conclusion, Notch2 ASOs successfully downregulate Notch2, Notch26955C>T, and Notch target
genes in mouse chondrocytes.

INTRODUCTION
Notch signaling is fundamental to many different tissues. Gain or loss of elements of Notch
signaling may result in a number of human disorders, including developmental diseases, immune
disorders, cancer, and skeletal diseases (1,2). In mammals, there are four Notch transmembrane
receptors (Notch1-4), all expressed in skeletal cells to varying degrees. NOTCH1 and NOTCH2
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are known to be expressed by cells of the osteoblast and osteoclast lineage, and NOTCH3 is
expressed by osteoblasts and osteocytes, but not by cells of the osteoclast lineage. NOTCH4 is
expressed in skeletal cells to a lesser extent and its functions are not as well known (3). NOTCH1
inhibits, while NOTCH2 induces, osteoclastogenesis and bone resorption (4). Osteoclastogenesis
is the development of osteoclasts from macrophages, and bone resorption is the process in which
osteoclasts break down the tissue in bones and release the minerals to blood (5). NOTCH2 also
impairs osteoblast maturation, which are responsible for bone formation (3). NOTCH3 induces
osteoclastogenesis by indirect mechanisms (6). Notch receptors are activated when interacting
with one of the five transmembrane ligands on a neighboring cell (Jagged1, Jagged2, Delta-like1,
Delta-like3, and Delta-like4). This paper focuses on NOTCH2 and uses JAGGED1 to induce
Notch activation. JAGGED1, encoded by JAG1, is a Notch ligand that is prevalent in skeletal cells.
JAGGED1 binds to and activates NOTCH2, among other Notch receptors (3, 7, 8).

Notch are transmembrane receptors with a complex structure. The extracellular domain is
responsible for interacting with Jagged or Delta-like ligands. In between the extracellular domain
and the transmembrane domain is the negative regulatory region (NRR), a site where cleavage
occurs after activation. The Notch intracellular domain (NICD) contains nuclear localization
sequences, required to regulate transcription (3). On the C-terminus of Notch lies the proline- (P),
glutamic acid- (E), serine- (S) and threonine- (T)- rich (PEST) domain (13). The PEST domain is
targeted by ubiquitin ligases for the proteasomal degradation of Notch (1). Each Notch receptor
carries out distinct functions in skeletal and non-skeletal cells. This is due to different patterns of
cellular expression, variation in the affinity of the Notch extracellular domain to the Delta-like and
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Jagged ligands, and variation in the NICD and hence diversified interaction between the NICD
and its nuclear targets.

Notch receptors are activated upon short-range cell-cell interaction with Jagged or Delta-like
ligands. Upon activation, the Notch receptor undergoes two proteolytic cleavage events. The first
is catalyzed by the ADAM-family of metalloproteases, whereas the second cleavage is catalyzed
by γ-secretase, releasing the NICD (9). The NICD is then released into the cell where it translocates
to the nucleus to associate with DNA-bound proteins (1). In the absence of a Notch signal and
hence NICD, the recombination signal-binding protein for immunoglobulin kappa J (RBP-Jκ)
represses Notch target genes through the recruitment of corepressor complexes (2). The NICD
associates with RBP-Jκ and mastermind (MAML) to activate transcription of Notch target genes
(10, 11). After transcription is activated, the NICD is released and degraded by cell proteosomes.

Hairy/Enhancer of split family genes (Hes) and Hes-related with YRPW motif (Hey), are wellestablished Notch target genes expressed in multiple cell types that encode transcription factors
(12). There are seven Hes proteins (Hes1-7), and all of them except Hes2 and Hes3 are targets of
the Notch canonical signaling pathway. There are three Hey transcription factors (Hey1, Hey2, and
HeyL), all targets of Notch (4). The Notch target genes that are analyzed in this paper are Hes1,
Hey1, Hey2, and HeyL. Hes1 preserves the undifferentiated state of precursor cells during
development and throughout cell life. Hes1, Hey1, Hey2, and HeyL have all been studied in the
skeleton and cartilage and have been shown to be expressed during chondrogenesis and
chondrocyte hypertrophy (13, 14).
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Figure 1. The Notch canonical signaling pathway, shown with NOTCH2. JAGGED1 binds to
NOTCH2 receptor, releasing the NICD into the cell. The NICD interacts with RBPJ and MAML
to enhance transcription of target genes Hes1, Hes4-7, and Hes-related family Hey1, Hey2, and
HeyL. The Notch target genes shown in this figure and investigated in the paper are Hes1, Hey1,
Hey2, and HeyL. Note: This is not a comprehensive diagram of all of the components involved in
the Notch signaling pathway, but rather the key points as described in this paper.

Hajdu Cheney Syndrome (HCS) is a monogenic disorder caused by gain-of-function NOTCH2
pathogenic variants. HCS is a disease in humans characterized by osteoporosis, bone fractures,
acro-osteolysis, wormian bones, and craniofacial developmental defects (15). As it is caused by
an overactive NOTCH2 protein, HCS causes increased osteoclastogenesis and bone resorption in
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mice (16). HCS is inherited as autosomal dominant and is associated with a truncated NOTCH2
protein. The mutant NOTCH2 protein is truncated directly upstream of the sequences coding for
the PEST domain, therefore creating a functional protein with a constitutively active NICD (17).
Without the PEST domain, the NICD is not degraded by cell proteosomes and is stable within the
cell, therefore gain-of-function. A mouse model heterozygous for this HCS mutation has been
previously created and termed Notch2tm1.1Ecan. The mouse line harbors a 6955C>T substitution in
Notch2 (7). This nucleotide substitution codes for a Q2319X amino acid change (a stop codon) in
the sequence upstream of the PEST domain and resulting in a truncated protein of 2318 amino
acids (17).

Antisense oligonucleotides (ASO) are short and single-stranded nucleotides that alter RNA by
binding to RNA sequences directly and inducing RNA degradation by RNase H, therefore
modifying protein expression (18, 19, 20). Notch2 antisense oligonucleotides have been shown to
downregulate Notch2 in cells of the spleen, kidney, and femur from Notch2wt/wt mice. In subsequent
experiments, the Notch target genes Hes1, Hey1, Hey2, and HeyL were shown to be induced in
bone extracts from mutant Notch2tm1.1Ecan mice and suppressed upon subcutaneous administration
of Notch2 ASO (21).
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Figure 2. The process by which antisense oligonucleotides (ASO) facilitate mRNA degradation
through recruitment of RNase H.

Chondrocytes are specialized cells that function to produce, sustain, and degrade the cartilage
extracellular matrix (22). Chondrogenesis is the process by which cartilage is formed:
mesenchymal cells, a type of multipotent stem cell, differentiate into chondrocytes. (23).
Chondrocytes in the hyaline cartilage undergo proliferation, hypertrophy, and apoptosis to be
gradually replaced by bone in a process known as endochondral ossification. The cartilaginous
scaffold that results from this allows for osteoblasts to replace the cartilage with bone. This process
forms the appendicular skeleton and parts of the axial skeleton. Bone is formed and remodeled
throughout one’s lifetime through coordination of osteoblasts and osteoclasts (24). Notch signaling
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plays a key role in the life cycle of chondrocytes. Notch signaling has been shown to suppress
chondrogenesis and promote the onset of chondrocyte hypertrophy, and it was shown that Notch2
controls the inhibitory effects of Notch on skeletal development (14, 25). Additionally, NOTCH2
gain-of-function has been documented in femoral heads of Notch2tm1.1Ecan mice and was shown to
sensitize Notch2tm1.1Ecan mice to osteoarthritis, a disease characterized by cartilage degradation
(26).

Because Notch signaling is involved in chondrocyte maturation and degradation, we asked the
question as to whether Notch2 ASO would downregulate Notch2 and Notch target genes in
chondrocytes from Notch2tm1.1Ecan mice. Successful downregulation of Notch2 in mice harboring
HCS could help to correct the effects of the gain-of-function HCS mutation. The effects of Notch2
ASO treatment on Notch2, Notch26955C>T, and Notch target genes Hes1, Hey1, Hey2, and HeyL,
were explored in chondrocytes from Notch2tm1.1Ecan mice and Notch2wt/wt mice in vitro and in vivo.

METHODS
Notch2tm1.1Ecan Mice
Notch2tm1.1Ecan mice were created previously in a C57BL/6 background to harbor a point 6955C>T
mutation in Notch2. Notch2tm1.1Ecan mice were crossed with wild type C57BL/6 mice for a yield of
50% heterozygous mutant and 50% wild type newborns. Newborn mice were tattooed on feet for
identification and their tails were snipped for genotyping. DNA was extracted from the tails using
the HotSHOT DNA extraction method (27). Genotyping was conducted in tail DNA extracts by
polymerase chain reaction (PCR) and the products were resolved through gel electrophoresis and
visualized

under

UV

light.

For

genotyping,
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forward

primer

Notch2Lox

gtF

5’-

CCCTTCTCTCTGTGCCGTAG

-3’

and

reverse

primer

Notch2Lox

gtR

5’-

CTCAGAGCCAAAGCCTCACTG -3’ were used. (Integrated DNA Technologies; IDT,
Coralville, IA).

Chondrocyte Cultures
The joints were dissected from the hind limbs of both male and female three- to four-day-old
Notch2tm1.1Ecan mice and Notch2wt/wt mice in phosphate-buffered saline (PBS), and placed in
Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies, Waltham, MA). The
chondrocyte-enriched cells were trypsinized in 0.25% trypsin-EDTA at 37°C for 40 minutes, and
then incubated while rotating in 200 units/mL of collagenase type 2-DMEM mix (Worthington
Biochemical Corporation, Lakewood, NJ) for 2 hours at 37°C, as described (26). The digested
cartilage was homogenized, strained through a 70 µM membrane, and centrifuged for 5 minutes.
Cells were suspended in DMEM with 10% fetal bovine serum (FBS) and 100 µg/mL ascorbic acid
(Sigma-Aldrich, St. Louis, MO) at 37°C and cultured in a 5% CO2 atmosphere, as described (26).
The culture was confirmed to consist of chondrocytes because gene markers characteristic of
chondrocytes were present, such as Type 2 collagen, type 10 collagen, and aggrecan. Cells were
then seeded on plates coated with JAGGED1 to activate Notch receptors. Either control ASO,
Notch2 ASO, or Notch26955C>T ASO (Ionis Pharmaceuticals, Carlsbad, California) were added to
the culture medium in varying amounts of dose and time, as stated in figure legends.

Notch2 Expression In Vivo
Control and Notch2 ASOs were injected subcutaneously at 50 mg/kg into 1–2-month-old
Notch2wt/wt mice and Notch2tm1.1Ecan mice. The animals were sacrificed 72 hours later, femoral
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heads were isolated, and RNA was subsequently extracted and reverse-transcribed in the presence
of specific primers for Notch2 and Notch26955C>T, as described (21).

RNA Integrity and Real Time Reverse Transcription Polymerase Chain Reaction
RNA was extracted from cell cultures with the RNeasy kit (Qiagen, Valencia, CA) and RNA
concentrations were measured via nanodrop spectrophotometer (Thermo Fisher Scientific,
Waltham, MA). The RNA integrity of a random sample from each group was assessed with a BioRad Experion microfluidic electrophoresis system (Bio-Rad, Hercules, CA). All RNA that was
analyzed had a quality indicator number higher than 9.0. RNA was treated with DNase and
subsequently reverse-transcribed using the iScript RT-PCR kit (Bio-Rad). Once converted to
cDNA, the samples were amplified in the presence of specific primers (Table 1) and SYBR green
in a Bio-Rad CFX96 thermal cycler. Copy number was estimated by comparison to a standard
curve of a serial dilution of cDNA for Notch2 (from Open Biosystems, Huntsville, AL), Hes1
(from American Type Culture Collection; ATCC, Manassas, VA), Hey1 and Hey2 (from T. Iso,
Los Angeles, CA), and HeyL (from D. Srivastava, Dallas, TX). Copy number was corrected for
expression of Rpl38. Rpl38 cDNA was obtained from ATCC. To determine the expression of the
mutant transcript, DNase-treated RNA was reverse-transcribed in the presence of specific primers
for the mutant transcript, with a 6955C>T substitution in Notch2, and with SYBR Universal Probe
and custom TaqMan assay probe, as described (7). The Notch26955C>T transcript copy number was
measured and corrected for Rpl38 expression. Fluorescence was monitored during every PCR
cycle at the annealing step, as described (26).
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GenBank
Gene

Sequence 5’-3’

Strand

Accession
Number

Notch2

Forward

5’-TGACGTTGATGAGTGTATCTCCAAGCC-3’

Reverse

5’- GTAGCTGCCCTGAGTGTTGTGG -3’

Forward 5’-AGAACAAGGATAATGTGAAGTTCAAGGTTC-3’
Rpl38

Hey1

Hey2

HeyL

Hes1

Reverse

5’-CTGCTTCAGCTTCTCTGCCTTT-3’

Forward

5’-ATCTCAACAACTACGCATCCCAGC -3’

Reverse

5’-GTGTGGGTGATGTCCGAAGG-3’

Forward

5’-AGCGAGAACAATTACCCTGGGCAC-3’

Reverse

5’-GGTAGTTGTCGGTGAATTGGACCT-3’

Forward

5’-CAGTAGCCTTTCTGAATTGCGAC-3’

Reverse

5’-AGCTTGGAGGAGCCCTGTTTC -3’

Forward

5’-ACCAAAGACGGCCTCTGAGCACAGAAAGT-3’

Reverse

5’-ATTCTTGCCCTTCGCCTCTT-3’

BQ186939.1
NM_001048057;
M_001048058;
NM_023372
NM_010423

NM_013904

NM_013905

NM_008235

Table 1. Primers used for qRT-PCR determinations.

Statistics
Data are expressed as means ± standard deviation (SD), and statistical differences were determined
by unpaired t-test for Figures 3, 4, 5, 7, and 8, and by two-way ANOVA with Tukey’s multiple
comparisons test for Figure 6.
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RESULTS
Effect of Notch2 ASOs on Notch2 and Notch26955C>T Expression in Chondrocytes
To determine the most effective duration of treatment, a time course experiment was conducted.
In cells from Notch2tm1.1Ecan mice, 10 µM control or Notch2 ASO were administered, and cells
cultured for 24 to 96 hours after the addition of the ASO. Notch2 mRNA expression increased
when cells were cultured for 72 hours in the presence of control ASO compared to cells cultured
for 24 hours. Addition of Notch2 ASO prevented the increase in Notch2 expression so that Notch2
ASO inhibited Notch2 expression with an effect that was maximal after 72 hours, proven
significant by unpaired t-test (Figure 3).

Figure 3. Time course experiment. Effect of 10 µM control or Notch2 ASO in chondrocytes from
Notch2tm1.1Ecan mice cultured on JAGGED1-coated plates for varying time periods. Data are shown
as Notch2 copy number corrected for Rpl38 expression. Values are means ± SD; n=3. *
Significantly different between the same dose of control ASO and Notch2 ASO after a certain
elapsed time, p < 0.05 by unpaired t-test.

To determine the effective dose of Notch2 ASOs, doses of 0, 5, 10, and 20 µM control and Notch2
ASO were added to chondrocyte cultures from Notch2tm1.1Ecan mice for 72 hours. Control ASO did
not have an effect on Notch2 expression. Administration of Notch2 ASO at doses of 5, 10, and 20
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µM to cells of Notch2tm1.1Ecan mice significantly decreased Notch2 expression, with a maximal
decrease at a dose of 20 µM (Figure 4A). Notch2tm1.1Ecan chondrocytes, cultured with 20 µM of
Notch2 ASO, showed significantly decreased expression of the HCS mutant transcript,
Notch26955C>T, compared to cells cultured with equivalent dose of control ASO (Figure 4B).
A

B

Figure 4. Effect of varying doses of control or Notch2 ASO in chondrocytes from Notch2tm1.1Ecan
mice cultured on JAGGED1-coated plates for 72 hours. Panel A shows Notch2 copy number
corrected for Rpl38 expression. Panel B shows expression of the HCS 6955C>T point mutation,
Notch26955C>T, as copy number corrected for Rpl38 expression. Values are means ± SD; n=3. *
Significantly different between the same dose of control ASO and Notch2 ASO, p < 0.05 by
unpaired t-test

To compare the effect of Notch2 ASOs on cells from wild type and mutant mice, expression of
Notch2 and Notch26955C>T transcripts were measured in wild type and mutant cells. In chondrocytes
from both Notch2wt/wt mice and Notch2tm1.1Ecan mice, Notch2 ASOs significantly decreased Notch2
mRNA expression at 20 µM, decreasing by 80% in mutant cells (Figure 5A-B). Chondrocytes
isolated from Notch2wt/wt mice did not express the HCS mutant transcript, Notch26955C>T. In cells
from Notch2tm1.1Ecan mice, expression of Notch26955C>T decreased by 50% when chondrocytes were
treated with 10 µM and 20 µM of Notch2 ASO, compared to control ASO (Figure 5C).
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A

B

C

Figure 5. Effect of varying doses of control or Notch2 ASOs in chondrocytes from Notch2wt/wt
mice and Notch2tm1.1Ecan mice cultured on JAGGED1-coated plates for 72 hours. Panel A shows
expression of Notch2 as copy number corrected for Rpl38 expression in Notch2wt/wt mice, Panel B
shows expression of Notch2 as copy number corrected for Rpl38 expression in Notch2tm1.1Ecan
mice, and Panel C shows expression of Notch26955C>T as copy number corrected for Rpl38
expression in Notch2tm1.1Ecan mice. Notch26955C>T was not detected in chondrocytes of Notch2wt/wt
mice. Values are means ± SD; n=3. * Significantly different between the same dose of control
ASO and Notch2 ASO, p < 0.05 by unpaired t-test.

Effect of Notch2 ASOs on the Expression of Notch Target Genes in Chondrocytes
We asked the question as to whether Notch signaling is present in chondrocytes. Expression of
the Notch target genes Hes1, Hey1, Hey2, and HeyL was significantly increased in Notch2tm1.1Ecan
chondrocytes, compared to chondrocytes from Notch2wt/wt mice when cultured on JAGGED1coated plates. (Figure 6). Expression of Hes1, Hey1, Hey2, and HeyL in chondrocytes from
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Notch2tm1.1Ecan mice decreased significantly when treated with 20 μM Notch2 ASO (Figures 6AD).
A

B

C

D

Figure 6. Effect of 20 µM control or Notch2 ASO on Hes1, Hey1, Hey2, and HeyL expression in
chondrocytes from Notch2wt/wt mice and Notch2tm1.1Ecan mice cultured on JAGGED1-coated plates
for 72 hours. Panels A-D show data expressed as copy number of Hes1, Hey1, Hey2, and HeyL,
corrected for Rpl38 expression. Values are means ± SD; n=3. * Significantly different between
control ASO and Notch2 ASO, p < 0.05; # significantly different between Notch2wt/wt mice and
Notch2tm1.1Ecan mice, p < 0.05 by two-way ANOVA with Tukey’s multiple comparisons test.
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Effect of Mutant-Specific Notch26955C>T ASO on Mutant Notch26955C>T Transcript Expression
Expression of Notch2 did not change in chondrocytes isolated from Notch2wt/wt mice and
Notch2tm1.1Ecan mice treated with mutant specific Notch26955C>T ASO (Figure 7A). In contrast,
expression of the mutant transcript, Notch26955C>T, significantly decreased by 83% in chondrocytes
from Notch2tm1.1Ecan mice when treated with the mutant specific Notch26955C>T ASO. As expected,
expression of Notch26955C>T was not detected in chondrocytes from Notch2wt/wt mice treated with
control or Notch26955C>T ASO (Figure 7B).
A

B

C

Figure 7. Effect of varying doses of mutant-specific Notch26955C>T ASO in chondrocytes from
Notch2wt/wt mice and Notch2tm1.1Ecan mice cultured on JAGGED1-coated plates for 72 hours. Panel
A shows expression of Notch2 copy number corrected for Rpl38 expression in Notch2wt/wt mice,
Panel B shows Notch2 copy number corrected for Rpl38 expression in Notch2tm1.1Ecan mice, and
Panel C shows expression of Notch26955C>T copy number corrected for Rpl38 expression. Values
are means ± SD; n=3. * Significantly different between the same dose of control ASO and Notch2
ASO, p < 0.05 by unpaired t-test.
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Effect of Notch2 ASOs on Notch2 and Notch26955C>T Expression In Vivo
Expression of Notch2 mRNA from Notch2wt/wt chondrocytes decreased by 22% following
subcutaneous injection of Notch2 ASO, although the effect did not reach statistical significance.
Expression of Notch2 mRNA from Notch2tm1.1Ecan chondrocytes showed a significant decrease
following injection of Notch2 ASO (Figure 8A). Expression of Notch26955C>T mRNA was not
detected in cartilage from Notch2wt/wt mice, as expected. In Notch2tm1.1Ecan mice, expression of
Notch26955C>T transcript decreased by 36% when mice were injected with Notch2 ASO compared
to control ASO, although the effect did not reach statistical significance (Figure 8B).
A

B

Figure 8. Effect of control and Notch2 ASOs on Notch2 and Notch26955C>T expression in
Notch2wt/wt mice and Notch2tm1.1Ecan mice in vivo. Data are shown as copy number of Notch2, Panel
A, and copy number of Notch26955C>T, Panel B, corrected for Rpl38 expression. Values are means
± SD; n=3. * Significantly different between the same dose of control ASO and Notch2 ASO, p <
0.05 by unpaired t-test.
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DISCUSSION
In this study, we report that wild type Notch2 ASO and mutant specific Notch2 ASO downregulate
Notch2 and Notch26955C>T expression, respectively, in chondrocyte cultures from Notch2tm1.1Ecan
mice. Notch2 ASO had the same effect on the expression of Notch2 mRNA in Notch2wt/wt mice
and Notch2tm1.1Ecan mice.

Previous work shows evidence of increased NOTCH2 signaling in cells of osteoblast, osteoclast,
and osteocyte cell cultures from Notch2tm1.1Ecan mice, and suppression of NOTCH2 activation upon
addition of Notch2 ASOs in these cultures (21). We raised the question as to whether Notch
signaling was present in cartilage tissue. Expression of the Notch target genes Hes1, Hey1, Hey2,
and HeyL was amplified in Notch2tm1.1Ecan mice compared to Notch2wt/wt mice, conforming to the
gain-of-function NOTCH2 mutation expected in HCS. Notch2 ASO significantly decreased
mRNA expression of Hes1, Hey1, Hey2, and HeyL in Notch2tm1.1Ecan mice, although levels of
mRNA expression in ASO-treated Notch2tm1.1Ecan chondrocytes were not as low as the mRNA
levels found in chondrocytes from Notch2wt/wt mice. This raises the concern that the Notch2 ASO
is not completely effective in targeting the Notch signaling pathway.

Transcripts from the mutant gene Notch26955C>T, indicative of HCS, were present in cells from
Notch2tm1.1Ecan mice, but not in Notch2wt/wt mice. Notch26955C>T mutant ASOs downregulated
Notch26955C>T in Notch2tm1.1Ecan mice but did not downregulate Notch2, indicating that it is specific
to the mutant transcript. This is consistent with the results of previous work, which found that
Notch26955C>T mRNA was present in osteocyte-enriched cultures only from Notch2tm1.1Ecan mice
and found that Notch2 ASOs suppressed Notch26955C>T mRNA levels in these cultures (21).
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Previous work showed a 50% downregulation of Notch2 mRNA in the spleen, kidney, femur, and
liver after subcutaneous administration of Notch2 ASO (21). In the present work, Notch2 ASOs
did not downregulate Notch2 in cartilage when administered in vivo subcutaneously as efficiently
as they did in vitro. This could be due to the limited vascularization of cartilage tissue, making it
difficult for the ASO to access this tissue. In an inflammatory disease state, however, systemic
administration of ASOs may be more effective, an effect that could be studied in the future.

Additional ways to apply ASOs in vivo are possible. Previous work revealed that mice harboring
the HCS mutation are sensitized to osteoarthritis (26). Because of this, ASOs may be effective in
vivo if they are applied in a localized fashion. This would directly deliver ASOs to cartilage tissue.
Although a systemic application would be more practical, local administration of ASO could be
more successful. Also, it may be worth studying the effects of an in vivo ASO applied for a longer
duration than 72 hours.

CONCLUSION
In conclusion, gain-of-function NOTCH2 signaling, indicative of HCS, is present in chondrocytes
from Notch2tm1.1Ecan mice. Notch2 ASOs downregulate Notch2 mRNA in vitro in chondrocyte
cultures from Notch2wt/wt mice and Notch2tm1.1Ecan mice, and Notch26955C>T ASOs downregulate
Notch26955C>T mRNA in vitro in chondrocyte cultures from Notch2tm1.1Ecan mice.
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